Lurker Nancy

SEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 6

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 70,126

Underlying: Common Stock · 10,906 shares

Expires 2030-02-28

F6 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 71,684 shares of Common Stock of the Company, of which 59,220 had been previously gifted on May 11, 2023.

F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 5

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,674

Underlying: Common Stock · 10,906 shares

Expires 2030-02-28

F6 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 71,684 shares of Common Stock of the Company, of which 59,220 had been previously gifted on May 11, 2023.

F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.

SEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 4

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 151,370

Underlying: Common Stock · 31,164 shares

Expires 2031-02-09

F4 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 151,370 shares of Common Stock of the Company, of which 120,206 had been previously gifted on May 11, 2023.

F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 3

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,330

Underlying: Common Stock · 31,164 shares

Expires 2031-02-09

F4 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 151,370 shares of Common Stock of the Company, of which 120,206 had been previously gifted on May 11, 2023.

F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

SEC source: 0001562180-24-000133 · primarydocument.xml · nonDerivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 52,208

F1 · date: This transaction was inadvertently left off of the original Form 4 filing on January 2, 2024.

F2 · kind: On December 28, 2023, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-000133 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,351

F1 · date: This transaction was inadvertently left off of the original Form 4 filing on January 2, 2024.

F2 · kind: On December 28, 2023, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust.

SEC source: 0001562180-23-008170 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 170,559

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $22.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-23-005880 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,666

Underlying: Common Stock · 66,666 shares

Expires 2033-07-10

F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months

SEC source: 0001562180-23-005880 · primarydocument.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,334

Underlying: Common Stock · 33,334 shares

Expires not disclosed

F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning July 10, 2024.

F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning July 10, 2024.

SEC source: 0001562180-23-005441 · primarydocument.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,400

Underlying: Common Stock · 225,400 shares

Expires not disclosed

F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.

F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 14

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2032-02-09

F14 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 75,000 shares of Common Stock of the Company.

F15 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of May 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 13

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,000

Underlying: Common Stock · 75,000 shares

Expires 2032-02-09

F14 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 75,000 shares of Common Stock of the Company.

F15 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of May 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 12

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 59,220

Underlying: Common Stock · 59,220 shares

Expires 2030-02-28

F12 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 59,220 shares of Common Stock of the Company.

F13 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 11

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,580

Underlying: Common Stock · 59,220 shares

Expires 2030-02-28

F12 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 59,220 shares of Common Stock of the Company.

F13 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 10

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 120,206

Underlying: Common Stock · 120,206 shares

Expires 2031-02-09

F10 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 120,206 shares of Common Stock of the Company.

F11 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of May 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 9

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,494

Underlying: Common Stock · 120,206 shares

Expires 2031-02-09

F10 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 120,206 shares of Common Stock of the Company.

F11 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of May 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 8

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 24,000

Underlying: Common Stock · 8,000 shares

Expires 2027-06-27

F8 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on December 15, 2017 and was fully vested at the time of the transfer,

F9 · derivative.exercise_date: The option vested and became exercisable in three equal annual installments beginning on June 27, 2018. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of June 27, 2020.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 7

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,000 shares

Expires 2027-06-27

F8 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on December 15, 2017 and was fully vested at the time of the transfer,

F9 · derivative.exercise_date: The option vested and became exercisable in three equal annual installments beginning on June 27, 2018. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of June 27, 2020.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 6

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 54,000

Underlying: Common Stock · 36,000 shares

Expires 2028-06-14

F6 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on June 14, 2018 and was fully vested at the time of the transfer.

F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments beginning on June 14, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of June 14, 2021.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 5

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 36,000 shares

Expires 2028-06-14

F6 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on June 14, 2018 and was fully vested at the time of the transfer.

F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments beginning on June 14, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of June 14, 2021.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 4

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 93,000

Underlying: Common Stock · 65,868 shares

Expires 2029-02-21

F4 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 21, 2019 and was fully vested at the time of the transfer

F5 · derivative.exercise_date: The option vests and becomes exercisable ratably in 48 monthly installments beginning on March 21, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of March 21,2023.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 3

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,868 shares

Expires 2029-02-21

F4 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 21, 2019 and was fully vested at the time of the transfer

F5 · derivative.exercise_date: The option vests and becomes exercisable ratably in 48 monthly installments beginning on March 21, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of March 21,2023.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 85,000

Underlying: Common Stock · 21,250 shares

Expires 2026-09-15

F1 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on December 12, 2016 and was exercisable for 85,000 shares of Common Stock of the Company. At the time of the transfer the option was fully vested.

F2 · derivative.exercise_date: The option vested and became exercisable in four equal annual installments beginning on September 15, 2017. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of September 15, 2020.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,250 shares

Expires 2026-09-15

F1 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on December 12, 2016 and was exercisable for 85,000 shares of Common Stock of the Company. At the time of the transfer the option was fully vested.

F2 · derivative.exercise_date: The option vested and became exercisable in four equal annual installments beginning on September 15, 2017. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of September 15, 2020.

SEC source: 0001562180-23-001330 · primarydocument.xml · derivative · entry 4

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,534

Underlying: Common Stock · 17,533 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

F3 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

SEC source: 0001562180-23-001330 · primarydocument.xml · derivative · entry 3

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 20,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three annual installments beginning February 9, 2023.

F2 · derivative.expiration_date: The restricted stock units vest in three annual installments beginning February 9, 2023.

SEC source: 0001562180-23-001330 · primarydocument.xml · nonDerivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-001330 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 2,745 shares acquired on January 31, 2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

SEC source: 0001562180-23-000347 · primarydocument.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,800

Underlying: Common Stock · 450,800 shares

Expires 2033-01-05

F1 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-22-002135 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,466 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units vested in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022.

F1 · derivative.expiration_date: The restricted stock units vested in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022.

SEC source: 0001562180-22-002135 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,281

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-22-001757 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,718

Underlying: Common Stock · 13,717 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning February 21, 2020.

F1 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning February 21, 2020.

SEC source: 0001562180-22-001757 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,815

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-22-001410 · primarydocument.xml · derivative · entry 4

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2032-02-09

F4 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-22-001410 · primarydocument.xml · derivative · entry 3

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires not disclosed

F3 · derivative.exercise_date: These restricted stock units will vest in three ratable annual installments beginning February 9, 2023.

F3 · derivative.expiration_date: These restricted stock units will vest in three ratable annual installments beginning February 9, 2023.

SEC source: 0001562180-22-001410 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,067

Underlying: Common Stock · 17,533 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

F2 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

SEC source: 0001562180-22-001410 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,098

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 3,019 shares acquired on January 31, 2022 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

SEC source: 0001562180-21-007116 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,546

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on May 27, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.90 to $20.765. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-004451 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,700

Underlying: Common Stock · 213,700 shares

Expires 2031-02-09

F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-21-004451 · primarydocument.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,600

Underlying: Common Stock · 52,600 shares

Expires not disclosed

F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.

F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.

SEC source: 0001214659-21-006717 · marketforms-53150.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001562180-21-004275 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Vests in three annual installments beginning on 14-Jun-2019

F1 · derivative.expiration_date: Vests in three annual installments beginning on 14-Jun-2019

SEC source: 0001562180-21-004275 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-21-001813 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,466

Underlying: Common Stock · 12,467 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022.

F1 · derivative.expiration_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022.

SEC source: 0001562180-21-001813 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,046

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-21-001521 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,718

Underlying: Common Stock · 13,717 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning February 21, 2020.

F2 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning February 21, 2020.

SEC source: 0001562180-21-001521 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,579

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 878 shares acquired on July 31, 2020 and 3,541 shares acquired on January 29, 2021 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

SEC source: 0001562180-20-004867 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,333

Underlying: Common Stock · 124,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022.

F1 · derivative.expiration_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022.

SEC source: 0001562180-20-004867 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 784,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-20-004716 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: On June 27, 2017, the reporting person was granted 120,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

F1 · derivative.expiration_date: On June 27, 2017, the reporting person was granted 120,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.